Surgeon Chang urges health insurance coverage for obesity drugs like Wegovy

Regulatory Easing And Cost Demands For Weight-Loss Medications

Addressing government oversight of GLP-1 receptor agonists, Chang stated that he is not opposed to regulations, but argued that authorities should simultaneously consider subsidizing treatments for individuals who genuinely need them. According to inews24 reporting, the surgeon criticized current restrictions as lacking sufficient evidence, noting that the medications lack the characteristics of causing fatal complications or chemical dependency. Alongside regulatory reform, Chang asserted that pharmaceutical manufacturers must lower drug prices to improve accessibility.

National Health Insurance Criteria For Bariatric Interventions

South Korea currently applies national health insurance to bariatric metabolic surgeries, though Chang described the coverage threshold as high. Based on inews24 coverage, public insurance applies when a patient’s body mass index (BMI) exceeds 35, or when the BMI surpasses 30 alongside at least one obesity-related comorbidity. Chang contrasted older weight-loss medications that suffered from unclear or low efficacy—and consequently lacked insurance support—with modern GLP-1 therapies, pointing out that these newer drugs deliver verifiable results in 60 to 70 out of 100 patients to justify public coverage for obese individuals.

Risks And Medical Concerns For Normal-Weight Users

Chang expressed strong apprehension regarding normal-weight individuals using obesity treatments strictly to achieve a slender physique. As detailed by inews24, Chang characterized the desire of clearly normal-weight individuals to become severely underweight as a psychiatric condition, warning that non-obese users face greater risks than benefits. Specifically, Chang cautioned that women who lack excess weight face heightened risks of developing osteoporosis because their bone structure is not strong enough to handle unwarranted pharmacological intervention.

Chang Gains Attention for Using Wegovy for Obesity

inews24 noted that Chang gained widespread attention and his distinctive nickname after successfully controlling his own severe obesity using Wegovy. The surgeon previously drew public notice on a YouTube appearance where he expressed intense frustration toward individuals with a normal BMI of 22 or 23 who complained of side effects after taking Wegovy or Mounjaro for cosmetic thinness. That frank commentary cemented his public persona before his recent television appearance on SBS.

National health insurance currently limits bariatric subsidy criteria to severe obesity thresholds while broader pharmaceutical coverage remains unlegislated.